Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 194848, 11 pages
http://dx.doi.org/10.1100/2012/194848
Review Article

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey

Received 31 October 2011; Accepted 21 December 2011

Academic Editors: Z. Bashshur and L. Pablo

Copyright © 2012 Burçin Yavuz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. Schwartz, S. Kotak, J. Mardekian, and J. M. Fain, “Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases,” BMC Ophthalmology, vol. 11, no. 1, article 14, 2011. View at Publisher · View at Google Scholar
  2. “Report of the dry eye workshop,” 2007, http://www.tearfilm.org/dewsreport/.
  3. P. D. O'Brien and L. M. T. Collum, “Dry eye: diagnosis and current treatment strategies,” Current Allergy and Asthma Reports, vol. 4, no. 4, pp. 314–319, 2004. View at Google Scholar · View at Scopus
  4. S. C. Pflugfelder, “Prevalence, burden, and pharmacoeconomics of dry eye disease,” American Journal of Managed Care, vol. 14, no. 3, supplement, pp. S102–S106, 2008. View at Google Scholar · View at Scopus
  5. S. C. Pflugfelder, “Antiinflammatory therapy for dry eye,” American Journal of Ophthalmology, vol. 137, no. 2, pp. 337–342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. E. Stern and S. C. Pflugfelder, “Inflammation in dry eye,” Ocular Surface, vol. 2, no. 2, pp. 124–130, 2004. View at Google Scholar · View at Scopus
  7. H. Liu, Y. Wang, and S. Li, “Advanced delivery of ciclosporin A: present state and perspective,” Expert Opinion on Drug Delivery, vol. 4, no. 4, pp. 349–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Aksungur, M. Demirbilek, E. B. Denkbaş, J. Vandervoort, A. Ludwig, and N. Ünlü, “Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies,” Journal of Controlled Release, vol. 151, no. 3, pp. 286–294, 2011. View at Publisher · View at Google Scholar
  9. C. Gupta and A. Chauhan, “Ophthalmic delivery of cyclosporine A by punctal plugs,” Journal of Controlled Release, vol. 150, no. 1, pp. 70–76, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. C. Peng and A. Chauhan, “Extended cyclosporine delivery by silicone-hydrogel contact lenses,” Journal of Controlled Release, vol. 154, no. 3, pp. 267–274, 2011. View at Publisher · View at Google Scholar
  11. M. A. Lemp, “Recent developments in dry eye management,” Ophthalmology, vol. 94, no. 10, pp. 1299–1304, 1987. View at Google Scholar · View at Scopus
  12. M. A. Lemp, “Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes,” The CLAO Journal, vol. 21, no. 4, pp. 221–232, 1995. View at Google Scholar · View at Scopus
  13. P. Mertzanis, L. Abetz, K. Rajagopalan et al., “The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample,” Investigative Ophthalmology & Visual Science, vol. 46, no. 1, pp. 46–50, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. E. Stern, R. W. Beuerman, R. I. Fox, J. Gao, A. K. Mircheff, and S. C. Pflugfelder, “The pathology of dry eye: the interaction between the ocular surface and lacrimal glands,” Cornea, vol. 17, no. 6, pp. 584–589, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. E. M. Graham, C. J. K. Ellis, M. D. Sanders, and W. I. McDonald, “Optic neuropathy in sarcoidosis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 49, no. 7, pp. 756–763, 1986. View at Google Scholar · View at Scopus
  16. K. S. Kunert, A. S. Tisdale, M. E. Stern, J. A. Smith, and I. K. Gipson, “Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes,” Archives of Ophthalmology, vol. 118, no. 11, pp. 1489–1496, 2000. View at Google Scholar · View at Scopus
  17. L. G. Anderson and N. Talal, “The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome,” Clinical and Experimental Immunology, vol. 10, no. 2, pp. 199–221, 1972. View at Google Scholar · View at Scopus
  18. O. Suwan-apichon, M. Rizen, R. Rangsin et al., “Botulinum toxin B-induced mouse model of keratoconjunctivitis sicca,” Investigative Ophthalmology & Visual Science, vol. 47, no. 1, pp. 133–139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. J. Petcher, H. P. Weber, and A. Rueegger, “Crystal and molecular structure of an iodo derivative of the cyclic undecapeptide cyclosporin A,” Helvetica Chimica Acta, vol. 59, no. 5, pp. 1480–1488, 1976. View at Google Scholar · View at Scopus
  20. N. El Tayar, A. E. Mark, P. Vallat, R. M. Brunne, B. Testa, and W. F. van Gunsteren, “Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations,” Journal of Medicinal Chemistry, vol. 36, no. 24, pp. 3757–3764, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. R. B. Nussenblatt, A. G. Palestine, C. C. Chan, G. Stevens Jr., S. D. Mellow, and S. B. Green, “Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis,” American Journal of Ophthalmology, vol. 112, no. 2, pp. 138–146, 1991. View at Google Scholar · View at Scopus
  22. S. Noble and A. Markham, “Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral),” Drugs, vol. 50, no. 5, pp. 924–941, 1995. View at Google Scholar · View at Scopus
  23. E. Donnenfeld and S. C. Pflugfelder, “Topical ophthalmic cyclosporine: pharmacology andclinical uses,” Survey of Ophthalmology, vol. 54, no. 3, pp. 321–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Sall, O. D. Stevenson, T. K. Mundorf, and B. L. Reis, “Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease,” Ophthalmology, vol. 107, no. 4, pp. 631–639, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. S. E. Wilson and H. D. Perry, “Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment,” Ophthalmology, vol. 114, no. 1, pp. 76–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Kuwano, H. Ibuki, N. Morikawa, A. Ota, and Y. Kawashima, “Cyclosporine A formulation affects its ocular distribution in rabbits,” Pharmaceutical Research, vol. 19, no. 1, pp. 108–111, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. H. D. Perry, R. Solomon, E. D. Donnenfeld et al., “Evaluation of topical cyclosporine for the treatment of dry eye disease,” Archives of Ophthalmology, vol. 126, no. 8, pp. 1046–1050, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Behrens, J. J. Doyle, L. Stern et al., “Dysfunctional tear syndrome: a Delphi approach to treatment recommendations,” Cornea, vol. 25, no. 8, pp. 900–907, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Lemp, “Management of dry eye disease,” American Journal of Managed Care, vol. 14, no. 3, supplement, pp. S88–S110, 2008. View at Google Scholar
  30. C. A. Utine and E. K. Akpek, “What ophthalmologists should know about Sjögren’s syndrome,” European Ophtalmic Review, vol. 4, no. 1, pp. 77–81, 2010. View at Google Scholar
  31. A. Macri, M. Rolando, and S. Pflugfelder, “A standardized visual scale for elevation of tear fluorescein clearance,” Ophthalmology, vol. 107, no. 7, pp. 1338–1343, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Calonge, “The treatment of dry eye,” Survey of Ophthalmology, vol. 45, supplement 2, pp. S227–S239, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Toda, N. Shinozaki, and K. Tsubota, “Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren's syndrome,” Cornea, vol. 15, no. 2, pp. 120–128, 1996. View at Google Scholar · View at Scopus
  34. J. Murube, A. Murube, and C. Zhuo, “Classification of artificial tears—II: additives and commercial formulas,” Advances in Experimental Medicine and Biology, vol. 438, pp. 705–715, 1998. View at Google Scholar · View at Scopus
  35. M. Oechsner and S. Keipert, “Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems—I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 47, no. 2, pp. 113–118, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Ludwig, N. Unlu, and M. van Ooteghem, “Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans,” International Journal of Pharmaceutics, vol. 61, no. 1-2, pp. 15–25, 1990. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Unlu, A. Ludwib, M. van Ooteghem, and A. A. Hincal, “Formulation of Carbopol 940 ophthalmic vehicles, and in vitro evaluation of the influence of simulated lacrimal fluid on their physico-chemical properties,” Pharmazie, vol. 46, no. 11, pp. 784–788, 1991. View at Google Scholar · View at Scopus
  38. N. Unlu, A. Ludwig, M. van Ooteghem, and A. A. Hincal, “A comparative rheological study on carbopol viscous solutions and, the evaluation of their suitability as the ophthalmic vehicles and artificial tears,” Pharmaceutica Acta Helvetiae, vol. 67, no. 1, pp. 5–10, 1992. View at Google Scholar · View at Scopus
  39. J. L. Ubels, M. D. McCartney, W. K. Lantz, J. Beaird, A. Dayalan, and H. F. Edelhauser, “Effects of preservative-free artificial tear solutions on corneal epithelial structure and function,” Archives of Ophthalmology, vol. 113, no. 3, pp. 371–378, 1995. View at Google Scholar · View at Scopus
  40. G. Geerling, S. MacLennan, and D. Hartwig, “Autologous serum eye drops for ocular surface disorders,” British Journal of Ophthalmology, vol. 88, no. 11, pp. 1467–1474, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Schrader, T. Wedel, R. Moll, and G. Geerling, “Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 244, no. 10, pp. 1345–1349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. P. I. Burgess, P. Koay, and P. Clark, “SmartPlug versus silicone punctal plug therapy for dry eye: a prospective randomized trial,” Cornea, vol. 27, no. 4, pp. 391–394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. T. Yen, S. C. Pflugfelder, and W. J. Feuer, “The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects,” American Journal of Ophthalmology, vol. 131, no. 3, pp. 314–323, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. S. C. Pflugfelder, D. Jones, Z. Ji, A. Afonso, and D. Monroy, “Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca,” Current Eye Research, vol. 19, no. 3, pp. 201–211, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. G. N. Foulks, “The evolving treatment of dry eye,” Ophthalmology Clinics of North America, vol. 16, no. 1, pp. 29–35, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. J. Quarterman, D. W. Johnson, D. C. Abele, J. L. Lesher Jr., D. S. Hull, and L. S. Davis, “Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline,” Archives of Dermatology, vol. 133, no. 1, pp. 49–54, 1997. View at Google Scholar · View at Scopus
  47. W. D. Mathers, D. Stovall, J. A. Lane, M. B. Zimmerman, and S. Johnson, “Menopause and tear function: the influence of prolactin and sex hormones on human tear production,” Cornea, vol. 17, no. 4, pp. 353–358, 1998. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Sahlin, E. Chen, T. Kaugesaar, H. Almqvist, K. Kjellberg, and G. Lennerstrand, “Effect of eyelid botulinum toxin injection on lacrimal drainage,” American Journal of Ophthalmology, vol. 129, no. 4, pp. 481–486, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Avisar, A. Robinson, I. Appel, Y. Yassur, and D. Weinberger, “Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis,” Cornea, vol. 19, no. 2, pp. 145–147, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. B. A. Schechter, “Ketorolac during the induction phase of cyclosporin-A therapy,” Journal of Ocular Pharmacology and Therapeutics, vol. 22, no. 2, pp. 150–154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. W. D. Mathers and A. M. Dolney, “Objective demonstration of tear stimulation with oral pilocarpine in dry eye patients,” Investigative Ophthalmology & Visual Science, vol. 41, no. 4, article S60, 2000. View at Google Scholar
  52. E. C. Kim, J. S. Choi, and C. K. Joo, “A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome,” American Journal of Ophthalmology, vol. 147, no. 2, pp. 206–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Selek, N. Ünlü, and A. A. Hincal, “An ophthalmic emulsion of retinoic acid,” S.T.P. Pharma Sciences, vol. 8, no. 5, pp. 323–326, 1998. View at Google Scholar · View at Scopus
  54. H. Selek, N. Ünlü, M. Orhan, and M. Irkeç, “Evaluation of retinoic acid ophthalmic emulsion in dry eye,” European Journal of Ophthalmology, vol. 10, no. 2, pp. 121–127, 2000. View at Google Scholar · View at Scopus
  55. Y. Çirpanli, N. Ünlü, S. Çaliş, and A. A. Hincal, “Formulation and in-vitro characterization of retinoic acid loaded poly (lactic-co-glycolic acid) microspheres,” Journal of Microencapsulation, vol. 22, no. 8, pp. 877–889, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. H. F. Stähelin, “The history of cyclosporin a (Sandimmune) revisited: another point of view,” Experientia, vol. 52, no. 1, pp. 5–13, 1996. View at Google Scholar · View at Scopus
  57. R. M. Wenger, “Synthesis of cyclosporine. Total syntheses of “cyclosporin A” and “cyclosporin H”, two fungal metabolites isolated from the species Tolypocladium inflatum GAMS,” Helvetica Chimica Acta, vol. 67, no. 2, pp. 502–525, 1984. View at Publisher · View at Google Scholar · View at Scopus
  58. D. L. Williams, “A comparative approach to topical cyclosporine therapy,” Eye, vol. 11, no. 4, pp. 453–464, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. D. BenEzra, G. Maftzir, C. de Courten, and P. Timonen, “Ocular penetration of cyclosporin A—III: the human eye,” British Journal of Ophthalmology, vol. 74, no. 6, pp. 350–352, 1990. View at Google Scholar · View at Scopus
  60. D. K. Olivero, M. G. Davidson, R. V. English, M. P. Nasisse, V. E. Jamieson, and T. M. Gerig, “Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs,” Journal of the American Veterinary Medical Association, vol. 199, no. 8, pp. 1039–1042, 1991. View at Google Scholar · View at Scopus
  61. C. Newton, B. M. Gebhardt, and H. E. Kaufman, “Topically applied cyclosporine in azone prolongs corneal allograft survival,” Investigative Ophthalmology & Visual Science, vol. 29, no. 2, pp. 208–215, 1988. View at Google Scholar · View at Scopus
  62. L. Cheeks, R. L. Kaswan, and K. Green, “Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea,” Current Eye Research, vol. 11, no. 7, pp. 641–649, 1992. View at Google Scholar · View at Scopus
  63. P. Furrer, J. M. Mayer, B. Plazonnet, and R. Gurny, “Ocular tolerance of preservatives on the murine cornea,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 47, no. 2, pp. 105–112, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. D. D. S. Tang-Liu, J. B. Richman, R. J. Weinkam, and H. Takruri, “Effects of four penetration enhancers on corneal permeability of drugs in vitro,” Journal of Pharmaceutical Sciences, vol. 83, no. 1, pp. 85–90, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Hickok, “Polyoxyethylene stearate,” in Handbook of Pharmaceutical Excipients, A. Wade and W. Paul, Eds., pp. 379–384, The Pharmaceutical Press, London, UK, 1994. View at Google Scholar
  66. J. K. Milani, U. Pleyer, A. Dukes et al., “Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye,” Ophthalmology, vol. 100, no. 6, pp. 890–896, 1993. View at Google Scholar · View at Scopus
  67. S. Ding and C. A. Irvine, “Nonirritating emulsions for sensitive tissue,” U.S. Patent 5,474,979, 1995.
  68. A. Zimmer, J. Kreuter, and J. R. Robinson, “Studies on the transport pathway of PBCA nanoparticles in ocular tissues,” Journal of Microencapsulation, vol. 8, no. 4, pp. 497–504, 1991. View at Google Scholar · View at Scopus
  69. A. M. De Campos, A. Sánchez, and M. J. Alonso, “Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A,” International Journal of Pharmaceutics, vol. 224, no. 1-2, pp. 159–168, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. O. Felt, P. Furrer, J. M. Mayer, B. Plazonnet, P. Buri, and R. Gurny, “Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention,” International Journal of Pharmaceutics, vol. 180, no. 2, pp. 185–193, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Shen, Y. Deng, X. Jin, Q. Ping, Z. Su, and L. Li, “Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution,” International Journal of Pharmaceutics, vol. 402, no. 1-2, pp. 248–253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. J. J. Reidy, B. M. Gebhardt, and H. E. Kaufman, “The collagen shield: a new vehicle for delivery of cyclosporin A to the eye,” Cornea, vol. 9, no. 3, pp. 196–199, 1990. View at Google Scholar · View at Scopus
  73. U. Pleyer, B. Elkins, D. Ruckert et al., “Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields,” Current Eye Research, vol. 13, no. 3, pp. 177–181, 1994. View at Google Scholar · View at Scopus
  74. B. M. Gebhardt and H. E. Kaufman, “Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine,” Journal of Ocular Pharmacology and Therapeutics, vol. 11, no. 3, pp. 319–327, 1995. View at Google Scholar · View at Scopus
  75. J. L. Bourges, F. Lallemand, E. Agla et al., “Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats,” Molecular Vision, vol. 12, pp. 1461–1466, 2006. View at Google Scholar · View at Scopus
  76. F. Lallemand, P. Furrer, O. Felt-Baeyens et al., “A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics,” International Journal of Pharmaceutics, vol. 295, no. 1-2, pp. 7–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Meadows, “Nonaqueous fluorinated drug delivery vehicle suspensions,” Patent US, 1992.
  78. C. A. Harper III, B. Khoobehi, G. A. Peyman, B. M. Gebhardt, and W. A. Dunlap, “Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits,” International Ophthalmology, vol. 17, no. 6, pp. 337–340, 1993. View at Google Scholar · View at Scopus
  79. A. A. Alghadyan, G. A. Peyman, B. Khoobehi, S. Milner, and K. R. Liu, “Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection,” International Ophthalmology, vol. 12, no. 2, pp. 101–104, 1988. View at Google Scholar · View at Scopus
  80. A. Apel, C. Oh, R. Chiu, B. Saville, Y. L. Cheng, and D. Rootman, “A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy,” Current Eye Research, vol. 14, no. 8, pp. 659–667, 1995. View at Google Scholar · View at Scopus
  81. J. Grisolano Jr. and G. A. Peyman, “Retinal toxicity study of intravitreal cyclosporin,” Ophthalmic Surgery, vol. 17, no. 3, pp. 155–156, 1986. View at Google Scholar · View at Scopus
  82. G. J. Jaffe, C. S. Yang, X. C. Wang, S. W. Cousins, R. P. Gallemore, and P. Ashton, “Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis,” Ophthalmology, vol. 105, no. 1, pp. 46–56, 1998. View at Publisher · View at Google Scholar · View at Scopus
  83. J. D. Nelson, H. Helms, R. Fiscella, Y. Southwell, and J. D. Hirsch, “A new look at dry eye disease and its treatment,” Advances in Therapy, vol. 17, no. 2, pp. 84–93, 2000. View at Google Scholar · View at Scopus
  84. M. M. Brown, G. C. Brown, H. C. Brown, J. Peet, and Z. Roth, “Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome,” Archives of Ophthalmology, vol. 127, no. 2, pp. 146–152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Adriaens, K. Dierckens, T. G. M. Bauters et al., “The mucosal toxicity of different benzalkonium chloride analogues evaluated with an alternative test using slugs,” Pharmaceutical Research, vol. 18, no. 7, pp. 937–942, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Monti, P. Chetoni, S. Burgalassi, M. Najarro, and M. F. Saettone, “Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation,” International Journal of Pharmaceutics, vol. 232, no. 1-2, pp. 139–147, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. B. Yavuz, E. Bilensoy, I. Vural, and M. Şumnu, “Alternative oral exemestane formulation: improved dissolution and permeation,” International Journal of Pharmaceutics, vol. 398, no. 1-2, pp. 137–145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Kanai, R. M. Alba, T. Takano et al., “The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops,” Transplantation Proceedings, vol. 21, no. 1, part 3, pp. 3150–3152, 1989. View at Google Scholar · View at Scopus
  89. D. W. Mueller, “Improved extemporaneous formulation of cyclosporine ophthalmic drops,” American Journal of Hospital Pharmacy, vol. 51, no. 24, pp. 3080–3081, 1994. View at Google Scholar · View at Scopus
  90. S. N. Rao, “Topical cyclosporine 0.05% for the prevention of dry eye disease progression,” Journal of Ocular Pharmacology and Therapeutics, vol. 26, no. 2, pp. 157–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Solch, P. I. Nadler, and M. H. Silverman, “Safety and tolerability of two percent cyclosporine (Sandimmune) ophthalmic ointment in normal volunteers,” Journal of Ocular Pharmacology, vol. 7, no. 4, pp. 301–312, 1991. View at Google Scholar · View at Scopus
  92. J. Sansom, K. C. Barnett, W. Neumann et al., “Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial,” Veterinary Record, vol. 137, no. 20, pp. 504–507, 1995. View at Google Scholar · View at Scopus
  93. S. Muchtar, S. Almog, M. T. Torracca, M. F. Saettone, and S. Benita, “A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits,” Ophthalmic Research, vol. 24, no. 3, pp. 142–149, 1992. View at Google Scholar · View at Scopus
  94. N. Naveh, S. Muchtar, and S. Benita, “Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits,” Journal of Ocular Pharmacology, vol. 10, no. 3, pp. 509–520, 1994. View at Google Scholar · View at Scopus
  95. F. Lallemand, O. Felt-Baeyens, K. Besseghir, F. Behar-Cohen, and R. Gurny, “Cyclosporine A delivery to the eye: a pharmaceutical challenge,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 56, no. 3, pp. 307–318, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. S. L. Law, K. J. Huang, and C. H. Chiang, “Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption,” Journal of Controlled Release, vol. 63, no. 1-2, pp. 135–140, 2000. View at Publisher · View at Google Scholar · View at Scopus
  97. S. S. Lee, H. Kim, N. S. Wang et al., “A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection,” Investigative Ophthalmology & Visual Science, vol. 48, no. 5, pp. 2023–2029, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Bozdag, K. Dillen, J. Vandervoort, and A. Ludwig, “The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D,L-lactide-glycolide) nanoparticles,” Journal of Pharmacy and Pharmacology, vol. 57, no. 6, pp. 699–707, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. K. Dillen, S. Bozdag, J. Vandervoort, and A. Ludwig, “Evaluation of the physicochemical characteristics and activity of various kinds of ciprofloxacin HCl-loaded cationic nanoparticles,” Journal of Drug Delivery Science and Technology, vol. 17, no. 1, pp. 49–56, 2007. View at Google Scholar · View at Scopus
  100. B. Calvo, A. Sanchez, J. Martinez et al., “Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A,” Pharmaceutical Research, vol. 13, no. 2, pp. 311–315, 1996. View at Publisher · View at Google Scholar
  101. P. Calvo, C. Thomas, M. J. Alonso, J. L. Vila-Jato, and J. R. Robinson, “Study of the mechanism of interaction of poly(ε-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy,” International Journal of Pharmaceutics, vol. 103, no. 3, pp. 283–291, 1994. View at Publisher · View at Google Scholar · View at Scopus
  102. C. A. Le Bourlais, F. Chevanne, B. Turlin et al., “Effect of cyclosporine A formulations on bovine corneal absorption: ex-vivo study,” Journal of Microencapsulation, vol. 14, no. 4, pp. 457–467, 1997. View at Publisher · View at Google Scholar · View at Scopus
  103. M. V. de Rojas Silva, M. T. Rodríguez-Ares, M. Sánchez-Salorio et al., “Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 237, no. 10, pp. 840–847, 1999. View at Publisher · View at Google Scholar
  104. T. Cavanak and H. Sucker, “Cyclosporin. Formulation of dosage forms,” Progress in Allergy, vol. 38, pp. 65–72, 1986. View at Google Scholar · View at Scopus
  105. A. Besarab, B. E. Jarrell, and S. Hirsch, “Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL,” Transplantation, vol. 44, no. 2, pp. 195–201, 1987. View at Google Scholar
  106. C. E. Freise, T. Liu, K. Hong et al., “The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome,” Transplantation, vol. 57, no. 6, pp. 928–932, 1994. View at Google Scholar · View at Scopus